Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19

Next Previous
Trial Profile

Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Codivir (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Therapeutic Use
  • Sponsors Code Pharma

Most Recent Events

  • 02 Oct 2024 Planned End Date changed from 20 Jul 2024 to 20 Jul 2025.
  • 02 Oct 2024 Planned primary completion date changed from 20 Jul 2024 to 20 Dec 2024.
  • 30 Aug 2023 Planned End Date changed from 20 Jul 2023 to 20 Jul 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top